|Dr. George Yancopoulos|
With blockbuster sales of Eylea spurring some gangbuster projections for Regeneron's future, the booming biotech today launched construction of a 300,000-square-foot R&D facility at its campus in Westchester County, NY.
BioMed Realty is building the R&D complex for Regeneron ($REGN), which plans to move its scientists into the new center in 2015. And a big group of VIPs--including New York Senator Charles Schumer--were on hand for the silver-spade event.
In addition to its ongoing Phase III program aimed at expanding the label for Eylea, Regeneron also has sarilumab (REGN88) in late-stage studies for rheumatoid arthritis. And analysts have been buzzing over the blockbuster prospects for alirocumab, its PCSK9 antibody for lowering bad cholesterol.
Regeneron CEO Leonard Schleifer and R&D director George Yancopoulos are regularly feted for growing Regeneron into an R&D powerhouse. Sanofi ($SNY) is closely allied to the company, and is relying on Regeneron to provide much of the Big Pharma's biggest innovations.
- here's the press release
Special Reports: 10 top drugs in biopharma's late-stage pipeline - Alirocumab | Top 15 highest paid biopharma R&D chiefs - George Yancopoulos